Yet again, Genomic Health, Inc. ( GHDX ) has announced positive study results that reaffirm the Oncotype DX test's recent development as a significant predictor of prostate cancer aggressiveness at the time of diagnosis – before intervention with radiation or surgery. A sub-analysis of a large Oncotype DX Genomic Prostate Score ( GPS ) development study was presented at the American Urological Association ( AUA.V ) Annual Meeting on May 20. This extensive development study helps patients overcome tumor heterogeneity and biopsy under-sampling and under-staging, which provides a precise individualized risk assessment at the time of diagnosis. The study demonstrated that GPS predicts time to clinical progression regardless of post-surgery treatment.